Clinical Trials Logo

Clinical Trial Summary

TAF treatment for HBV prophylaxis could lead to significant reduction in ALT and significant improvement in renal function. However, data are scarce regarding to TAF monotherapy without HBIG for HBV prophylaxis in post orthotopic liver transplant with HBV-related disease. This study is based on a real-world, multi-center, prospective study to assess the effectiveness and safety of TAF for HBV prophylaxis, which will fill in gaps with TAF monotherapy without HBIG in post liver transplant.


Clinical Trial Description

LT has evolved rapidly, becoming the standard therapy for acute and chronic liver failure of a variety of aetiologies, with more than 80,000 procedures performed to date [13]. HBV infection is a worldwide public health problem, especially in China. The need for an antiviral treatment with NAs for liver transplant recipients has two objectives: the improvement of liver function and to decrease the risk of HBV recurrence after transplant. TAF, TDF and ETV are currently the first-line therapy in patients with CHB in all CHB treatment guidelines, which have a greater potency and higher barriers to resistance. TAF treatment for HBV prophylaxis could lead to significant reduction in ALT and significant improvement in renal function. However, data are scarce regarding to TAF monotherapy without HBIG for HBV prophylaxis in post orthotopic liver transplant with HBV-related disease. This study is based on a real-world, multi-center, prospective study to assess the effectiveness and safety of TAF for HBV prophylaxis, which will fill in gaps with TAF monotherapy without HBIG in post liver transplant. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05063071
Study type Interventional
Source Fudan University
Contact
Status Active, not recruiting
Phase Phase 4
Start date July 29, 2021
Completion date December 29, 2022

See also
  Status Clinical Trial Phase
Completed NCT05442437 - Clinical Study of hUC-MSCs Treating Decompensated Liver Cirrhosis With HBV Early Phase 1
Not yet recruiting NCT05951751 - The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM) N/A
Completed NCT04519710 - Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies N/A
Recruiting NCT04562051 - Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients
Recruiting NCT04683341 - Tenofovir Alafenamide in HBV Related Decompensated Liver Phase 4
Active, not recruiting NCT02344680 - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Completed NCT02044068 - Hepatitis B Virus Vertical Transmission From HIV-HBV Co-infected Women N/A
Completed NCT03239353 - A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects Phase 1
Recruiting NCT04904835 - Access HBV Assays - European Union (EU) Clinical Trial Protocol -
Terminated NCT04059198 - Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus Phase 2
Not yet recruiting NCT05293158 - Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study N/A
Not yet recruiting NCT05028322 - Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen Phase 2
Completed NCT02312531 - Prevention for Mother-to-infant Transmission of HBV N/A
Not yet recruiting NCT01556815 - Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma Phase 2
Recruiting NCT05786859 - The Efficacy and Safety of Rifaximin Treatment Early Phase 1
Not yet recruiting NCT06307808 - Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination
Completed NCT03149627 - Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults
Recruiting NCT04886336 - The Impact of Tenofovir Alafenamide on Profiles of Body Weight and Metabolic Features in Chronic Hepatitis B Patients.
Recruiting NCT04568265 - A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B Phase 2
Terminated NCT02826018 - A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection Phase 1